Overview

Long-Term Follow-Up Study for Safety, Efficacy and Tolerability of Rotigotine in Adolescents With Restless Legs Syndrome

Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, multicenter, open-label, single-arm, optimal dose, long-term follow-up study of monotherapy administration of rotigotine transdermal patch in adolescents with Restless Legs Syndrome (RLS). This study will assess the long-term safety and tolerability of Rotigotine treatment in adolescents with RLS.
Phase:
Phase 2
Details
Lead Sponsor:
UCB BIOSCIENCES, Inc.
Treatments:
N 0437
Rotigotine